Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

Bristol Myers Squibb leapt into the drug industry’s most intense new rivalry on Monday, signing a deal to potentially spend ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...